Dapeng Lu1, Peng Luo1, Qi Wang1, Yuanyuan Ye1, Baolong Wang2. 1. Department of Clinical Laboratory, Affiliated Provincial Hospital of Anhui Medical University, Hefei, China. 2. Department of Clinical Laboratory, Affiliated Provincial Hospital of Anhui Medical University, Hefei, China. Electronic address: wbl196555@163.com.
Abstract
OBJECTIVES: Plasmacytoma variant translocation 1 (PVT1) is a newly discovered long non-coding RNA that functions as an oncogenic molecule in different cancers. We conducted a systematic review and meta-analysis to determine its prognostic potential for malignant tumors. MATERIALS AND METHODS: A literature survey was conducted by searching the PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure and Wanfang electronic databases for articles published as of June 1, 2017. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated to demonstrate the relationship between PVT1 expression and overall survival (OS) and disease-free survival (DFS) using RevMan 5.2 and Stata 12.0 software. A quality assessment of the included studies was performed according to the Newcastle-Ottawa scale. RESULTS: A total of 1443 patients from 15 studies were included in this meta-analysis. Elevated PVT1 expression was significantly correlated with poor overall survival (HR=2.03, 95% CI: 1.69-2.43) and disease-free survival (HR=1.55, 95% CI: 1.29-1.87). Statistical significance was also observed in a subgroup meta-analysis that was stratified by variance analysis, cancer type, sample size and PVT1 cut-off value. Additionally, increased PVT1 expression was significantly associated with positive lymph node metastasis (odds ratio (OR)=1.94, 95% CI: 1.03-3.68), positive distant metastasis (OR=3.85, 95% CI: 2.14-6.93), advanced tumor-node-metastasis stage (OR=3.19, 95% CI: 2.45-4.15) and poor differentiation grade (OR=1.57, 95% CI: 1.15-2.16), but not tumor size (P>0.05). CONCLUSION: Elevated PVT1 expression was related to poor prognosis and might be a potential biomarkerof clinicopathological characteristics in different cancer types. More studies need to be conducted to verify the clinical value of PVT1 in human cancers.
OBJECTIVES:Plasmacytoma variant translocation 1 (PVT1) is a newly discovered long non-coding RNA that functions as an oncogenic molecule in different cancers. We conducted a systematic review and meta-analysis to determine its prognostic potential for malignant tumors. MATERIALS AND METHODS: A literature survey was conducted by searching the PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure and Wanfang electronic databases for articles published as of June 1, 2017. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated to demonstrate the relationship between PVT1 expression and overall survival (OS) and disease-free survival (DFS) using RevMan 5.2 and Stata 12.0 software. A quality assessment of the included studies was performed according to the Newcastle-Ottawa scale. RESULTS: A total of 1443 patients from 15 studies were included in this meta-analysis. Elevated PVT1 expression was significantly correlated with poor overall survival (HR=2.03, 95% CI: 1.69-2.43) and disease-free survival (HR=1.55, 95% CI: 1.29-1.87). Statistical significance was also observed in a subgroup meta-analysis that was stratified by variance analysis, cancer type, sample size and PVT1 cut-off value. Additionally, increased PVT1 expression was significantly associated with positive lymph node metastasis (odds ratio (OR)=1.94, 95% CI: 1.03-3.68), positive distant metastasis (OR=3.85, 95% CI: 2.14-6.93), advanced tumor-node-metastasis stage (OR=3.19, 95% CI: 2.45-4.15) and poor differentiation grade (OR=1.57, 95% CI: 1.15-2.16), but not tumor size (P>0.05). CONCLUSION: Elevated PVT1 expression was related to poor prognosis and might be a potential biomarkerof clinicopathological characteristics in different cancer types. More studies need to be conducted to verify the clinical value of PVT1 in humancancers.